1
|
Lou J, Zhang L, Lv S, Zhang C and Jiang S:
Biomarkers for hepatocellular carcinoma. Biomark Cancer. 9:1–9.
2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Burkhart RA, Ronnekleiv-Kelly SM and
Pawlik TM: Personalized therapy in hepatocellular carcinoma:
Molecular markers of prognosis and therapeutic response. Surg
Oncol. 26:138–145. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Luz FA, Brigido PC, Moraes AS and Silva
MJ: Aberrant splicing in cancer: Mediators of malignant progression
through an imperfect splice program shift. Oncology. 92:3–13. 2017.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Ding C, Li Y, Guo F, Jiang Y, Ying W, Li
D, Yang D, Xia X, Liu W, Zhao Y, et al: A cell-type-resolved liver
proteome. Mol Cell Proteomics. 15:3190–3202. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Merkin J, Russell C, Chen P and Burge CB:
Evolutionary dynamics of gene and isoform regulation in Mammalian
tissues. Science. 338:1593–1599. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang J and Manley JL: Misregulation of
pre-mRNA alternative splicing in cancer. Cancer Discov.
3:1228–1237. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Villegas-Ruiz V, Hendlmeier F,
Buentello-Volante B, Rodriguez-Loaiza JL, Miranda-Duarte A and
Zenteno JC: Genome-wide mRNA analysis reveals a TUBD1 isoform
profile as a potential biomarker for diabetic retinopathy
development. Exp Eye Res. 155:99–106. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z
and He J: Prognostic alternative mRNA splicing signature in
non-small cell lung cancer. Cancer Lett. 393:40–51. 2017.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Singh B and Eyras E: The role of
alternative splicing in cancer. Transcription. 8:91–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
10
|
He C, Zhou F, Zuo Z, Cheng H and Zhou R: A
global view of cancer-specific transcript variants by subtractive
transcriptome-wide analysis. PLoS One. 4:e47322009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Laversin SA, Phatak VM, Powe DG, Li G,
Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I,
et al: Identification of novel breast cancer-associated transcripts
by UniGene database mining and gene expression analysis in normal
and malignant cells. Genes Chromosomes Cancer. 52:316–329. 2013.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Wang X, Sheng P, Guo X, Wang J, Hou L, Hu
G, Luo C, Dong Y and Lu Y: Identification and expression of a novel
MDM4 splice variant in human glioma. Brain Res 1537. 260–266.
2013.
|
13
|
Arafat H, Lazar M, Salem K, Chipitsyna G,
Gong Q, Pan TC, Zhang RZ, Yeo CJ and Chu ML: Tumor-specific
expression and alternative splicing of the COL6A3 gene in
pancreatic cancer. Surgery. 150:306–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kim YJ and Kim HS: Alternative splicing
and its impact as a cancer diagnostic marker. Genomics Inform.
10:74–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lin KT, Shann YJ, Chau GY, Hsu CN and
Huang CY: Identification of latent biomarkers in hepatocellular
carcinoma by ultra-deep whole-transcriptome sequencing. Oncogene.
33:4786–4794. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong
KJ, Liu M, Song Y, Chow RK, Ng VH, et al: A disrupted RNA editing
balance mediated by ADARs (Adenosine DeAminases that act on RNA) in
human hepatocellular carcinoma. Gut. 63:832–843. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Trapnell C, Pachter L and Salzberg SL:
TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics.
25:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Reshef DN, Reshef YA, Finucane HK,
Grossman SR, McVean G, Turnbaugh PJ, Lander ES, Mitzenmacher M and
Sabeti PC: Detecting novel associations in large data sets.
Science. 334:1518–1524. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Thorvaldsdottir H, Robinson JT and Mesirov
JP: Integrative genomics viewer (IGV): High-performance genomics
data visualization and exploration. Brief Bioinform. 14:178–192.
2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yu G, Wang LG, Han Y and He QY:
ClusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Shen S, Park JW, Huang J, Dittmar KA, Lu
ZX, Zhou Q, Carstens RP and Xing Y: MATS: A Bayesian framework for
flexible detection of differential alternative splicing from
RNA-Seq data. Nucleic Acids Res. 40:e612012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shen S, Park JW, Lu ZX, Lin L, Henry MD,
Wu YN, Zhou Q and Xing Y: rMATS: Robust and flexible detection of
differential alternative splicing from replicate RNA-Seq data. Proc
Natl Acad Sci USA. 111:E5593–E5601. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Chen Z, Chen L, Qiao SW, Nagaishi T and
Blumberg RS: Carcinoembryonic antigen-related cell adhesion
molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J
Immunol. 180:6085–6093. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Le KQ, Prabhakar BS, Hong WJ and Li LC:
Alternative splicing as a biomarker and potential target for drug
discovery. Acta Pharmacol Sin. 36:1212–1218. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wojtuszkiewicz A, Assaraf YG, Maas MJ,
Kaspers GJ, Jansen G and Cloos J: Pre-mRNA splicing in cancer: The
relevance in oncogenesis, treatment and drug resistance. Expert
Opin Drug Metab Toxicol. 11:673–689. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Williams AF and Barclay AN: The
immunoglobulin superfamily-domains for cell surface recognition.
Annu Rev Immunol. 6:381–405. 1988. View Article : Google Scholar : PubMed/NCBI
|
29
|
Cruz PV, Wakai T, Shirai Y, Yokoyama N and
Hatakeyama K: Loss of carcinoembryonic antigen-related cell
adhesion molecule 1 expression is an adverse prognostic factor in
hepatocellular carcinoma. Cancer. 104:354–360. 2005. View Article : Google Scholar : PubMed/NCBI
|
30
|
Kiriyama S, Yokoyama S, Ueno M, Hayami S,
Ieda J, Yamamoto N, Yamaguchi S, Mitani Y, Nakamura Y, Tani M, et
al: CEACAM1 long cytoplasmic domain isoform is associated with
invasion and recurrence of hepatocellular carcinoma. Ann Surg
Oncol. 21 Suppl 4:S505–S514. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lawson EL, Mills DR, Brilliant KE and
Hixson DC: The transmembrane domain of CEACAM1-4S is a determinant
of anchorage independent growth and tumorigenicity. PLoS One.
7:e296062012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhu J, Yang Y, Ma C, Zhang G, Wang K and
Hu S: CEACAM1 cytoplastic expression is closely related to tumor
angiogenesis and poorer relapse-free survival after curative
resection of hepatocellular carcinoma. World J Surg. 35:2259–2265.
2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kobel M, Kalloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al:
Ovarian carcinoma subtypes are different diseases: Implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Viasus D, Del Rio-Pertuz G, Simonetti AF,
Garcia-Vidal C, Acosta-Reyes J, Garavito A and Carratalà J:
Biomarkers for predicting short-term mortality in
community-acquired pneumonia: A systematic review and
meta-analysis. J Infect. 72:273–282. 2016. View Article : Google Scholar : PubMed/NCBI
|